Politi, Angeliki Louiza2021-03-192021-03-192021http://hdl.handle.net/10230/46867Master in Health Economics and Pharmacoeconomics (UPF Barcelona School of Management) Curs 2018-2021Mentor: Carlos CrespoThe purpose of this study is to conclude as to whether it is cost-effective to introduce genotyping in the Norwegian clinical practice in the case of acute coronary syndrome, as a guide of pharmacotherapy decision making after a percutaneous coronary intervention.application/pdfengThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International LicenseTreball de fi de màster – Curs 2020-2021ClopidogrelTicagrelorPercuntaneous coronary interventioneconomic evaluationcost.effectivenessCYPantiplateletsA cost-effectiveness analysis in a Norwegian setting: Introducing genotyping to patients with ACS treated with PCI before prescribing antiplatelet therapyinfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccess